C105

Cognition Pharmaceuticals, LLC · Phase 2 active Small molecule

At a glance

Generic name	C105
Sponsor	Cognition Pharmaceuticals, LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing. (PHASE1)
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

C105 CI brief — competitive landscape report
C105 updates RSS · CI watch RSS
Cognition Pharmaceuticals, LLC portfolio CI